GGrantIndex
← Leaderboards

Michael S Kuhns

University Of Arizona

$7,740,111
Attributed
$10,689,896
Total exposure
8
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.7M · FY201225
$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,689,896 · 8

By mechanism

R01$8,225,361 · 3
R21$1,686,752 · 4
R56$777,783 · 1

Top collaborators

Most similar at University Of Arizona

Same institution · by research overlap

Others in their field

Top investigators on “Response

Research focus

ResponseIn VivoT-LymphocyteCd4 Positive T LymphocytesT-Cell ReceptorPeptidesT Cell ResponseCd3 AntigensDesignSignal TransductionChimeric Antigen ReceptorEngineeringIn VitroMediatingReceptorMolecularCellsComplexAntigensBaseGenerationsReportingAntigen-Presenting CellsInsight

Grant awards (24)

Engineering 2nd generation 5MCARs to monitor and treat Type-I Diabetes$824,415
R01 · FY2025 · DK · contact PI
Evolution-guided analysis of extracellular and intracellular mechanisms driving T cell activation$676,106
R01 · FY2025 · AI · contact PI
Use of allogeneic pMHCII-based 5MCAR-CTLs to eliminate alloreactive lymphocytes in transplant$227,708
R21 · FY2025 · AI
Engineering 2nd generation 5MCARs to monitor and treat Type-I Diabetes$828,648
R01 · FY2024 · DK · contact PI
Evolution-guided analysis of extracellular and intracellular mechanisms driving T cell activation$682,433
R01 · FY2024 · AI · contact PI
Use of allogeneic pMHCII-based 5MCAR-CTLs to eliminate alloreactive lymphocytes in transplant$209,750
R21 · FY2024 · AI
Engineering 2nd generation 5MCARs to monitor and treat Type-I Diabetes$831,071
R01 · FY2023 · DK · contact PI
Engineering and Testing of Biomimetic Stimulators for Therapeutic Applications$230,250
R21 · FY2023 · EB · contact PI
Adapting 5MCAR technology for the treatment of peripheral T cell lymphoma$217,900
R21 · FY2023 · CA · contact PI
Engineering 2nd generation 5MCARs to monitor and treat Type-I Diabetes$841,657
R01 · FY2022 · DK · contact PI
Engineering and Testing of Biomimetic Stimulators for Therapeutic Applications$191,875
R21 · FY2022 · EB · contact PI
Adapting 5MCAR technology for the treatment of peripheral T cell lymphoma$187,144
R21 · FY2022 · CA · contact PI
Probing the mechanistic basis for T cell fate decisions (R01)$403,640
R01 · FY2021 · AI · contact PI
Development of Cellular Tools and Techniques to Identify Low Affinity T Cells$191,875
R21 · FY2021 · AI · contact PI
Inducing Tolerance with 5-Module chimeric Antigen Receptor (5MCAR) T Cells$777,783
R56 · FY2020 · AI · contact PI
Probing the mechanistic basis for T cell fate decisions (R01)$407,106
R01 · FY2020 · AI · contact PI
Development of Cellular Tools and Techniques to Identify Low Affinity T Cells$230,250
R21 · FY2020 · AI · contact PI
Probing the mechanistic basis for T cell fate decisions (R01)$408,682
R01 · FY2019 · AI · contact PI
Probing the mechanistic basis for T cell fate decisions (R01)$413,287
R01 · FY2018 · AI · contact PI
Probing the mechanistic basis for T cell fate decisions (R01)$416,041
R01 · FY2017 · AI · contact PI
Probing the mechanistic basis for T cell fate decisions (R01)$378,750
R01 · FY2015 · AI · contact PI
Probing the mechanistic basis for T cell fate decisions (R01)$378,750
R01 · FY2014 · AI · contact PI
Probing the mechanistic basis for T cell fate decisions (R01)$356,025
R01 · FY2013 · AI · contact PI
Probing the mechanistic basis for T cell fate decisions (R01)$378,750
R01 · FY2012 · AI · contact PI